NEOS Investment Management LLC Invests $192,000 in Verve Therapeutics, Inc. (NASDAQ:VERV)

NEOS Investment Management LLC acquired a new position in Verve Therapeutics, Inc. (NASDAQ:VERVFree Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 13,787 shares of the company’s stock, valued at approximately $192,000.

A number of other institutional investors have also made changes to their positions in VERV. ARK Investment Management LLC increased its stake in shares of Verve Therapeutics by 35.1% in the fourth quarter. ARK Investment Management LLC now owns 7,025,116 shares of the company’s stock worth $97,930,000 after purchasing an additional 1,824,549 shares during the period. Federated Hermes Inc. increased its stake in Verve Therapeutics by 57.2% during the fourth quarter. Federated Hermes Inc. now owns 3,980,372 shares of the company’s stock valued at $55,486,000 after acquiring an additional 1,448,003 shares during the period. Vanguard Group Inc. increased its stake in Verve Therapeutics by 18.1% during the third quarter. Vanguard Group Inc. now owns 4,832,968 shares of the company’s stock valued at $64,085,000 after acquiring an additional 741,753 shares during the period. FMR LLC increased its stake in Verve Therapeutics by 8.8% during the third quarter. FMR LLC now owns 6,577,562 shares of the company’s stock valued at $87,218,000 after acquiring an additional 531,182 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its stake in Verve Therapeutics by 11.7% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,397,604 shares of the company’s stock valued at $33,423,000 after acquiring an additional 250,361 shares during the period. 97.11% of the stock is currently owned by institutional investors.

Insider Transactions at Verve Therapeutics

In other Verve Therapeutics news, insider Andrew D. Ashe bought 76,000 shares of Verve Therapeutics stock in a transaction dated Tuesday, May 14th. The shares were acquired at an average cost of $6.26 per share, with a total value of $475,760.00. Following the acquisition, the insider now directly owns 342,509 shares of the company’s stock, valued at $2,144,106.34. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 19.30% of the stock is owned by company insiders.

Verve Therapeutics Stock Down 1.3 %

NASDAQ VERV opened at $5.21 on Friday. The stock’s 50 day moving average is $6.56 and its two-hundred day moving average is $10.87. Verve Therapeutics, Inc. has a 1-year low of $4.90 and a 1-year high of $21.42.

Verve Therapeutics (NASDAQ:VERVGet Free Report) last announced its earnings results on Wednesday, May 8th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.11. The business had revenue of $5.70 million for the quarter, compared to the consensus estimate of $2.11 million. Verve Therapeutics had a negative return on equity of 37.35% and a negative net margin of 1,226.51%. Verve Therapeutics’s revenue was up 305.6% compared to the same quarter last year. Research analysts predict that Verve Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Verve Therapeutics in a research note on Thursday, May 9th. Royal Bank of Canada restated an “outperform” rating and set a $35.00 price target on shares of Verve Therapeutics in a research note on Wednesday, February 28th. Finally, Stifel Nicolaus lowered their price target on Verve Therapeutics from $56.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

View Our Latest Stock Report on Verve Therapeutics

Verve Therapeutics Profile

(Free Report)

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

Featured Articles

Want to see what other hedge funds are holding VERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verve Therapeutics, Inc. (NASDAQ:VERVFree Report).

Institutional Ownership by Quarter for Verve Therapeutics (NASDAQ:VERV)

Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.